Antithrombotic treatment of radial artery occlusion
death, radial artery occlusion, bleeding
BLEEDING
Patients diagnosed with a new radial artery occlusion received the recommendation for oral anticoagulation regardless of symptoms for at least 30 days according to the local standard of care. These patients were also scheduled for a clinical follow-up after 30 days. Of the 93 patients with radial artery occlusion, a complete follow-up including a repeat duplex sonography was available in 94% of patients (87 of 93). The reason for missing follow-up in the remaining six patients were non-cardiovascular death in two patients and patient refusal in 4 patients (mainly due to long distance travelling or limited mobility due to comorbidities). From the remaining 87 patients, 82% (71/87) received an oral anticoagulation. Key reasons for missing oral anticoagulation were planned major surgery within the next few days (mainly bypass and/or valve surgery) or an estimated high bleeding risk according to the treating physician (mainly history of recent major bleeding or high age).The selection of oral anticoagulation was left to the treating physician. The majority of patients received NOACs (66 out of 71: rivaroxaban The reperfusion rate of the radial artery at 30 days was 13% in patients receiving no oral anticoagulation and 32% in patients with oral anticoagulation. The highest reperfusion rate was seen in patients anticoagulated with phenprocoumon (4 out of 5; Fig. Reperfusion rates of radial artery at 30 days. 